| Autor: |
Lucia Coli, Giselle Romero Caimi, Facundo Diaz Kozak, Zahira Deza, Laura Alvarez, Ezequiel Ridruejo |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology, Vol 29, Iss , Pp 101663- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1665-2681 |
| DOI: |
10.1016/j.aohep.2024.101663 |
| Popis: |
Conflict of interest: No Introduction and Objectives: Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the fifth leading cause of cancer death. Hexachlorobenzene (HCB) is an environmental pollutant and endocrine disruptor. It plays a role in hepatocarcinogenesis by promoting angiogenesis and cell proliferation, partly by altering thyroid hormones, regulators of the cell cycle.We previously demonstrated that HCB deregulates liver growth, involving TGF-β1 and triiodothyronine (T3); and that Atorvastatin (AT) prevents these effects. Objective: To evaluate the capacity of AT to reverse the effects generated by HCB in the early stages of HCC development. Patients / Materials and Methods: We analyzed the effect of HCB (5μM) with/without AT (20μM) in Huh-7 cell line on 1-(PCNA), 2-(caspase-3 and cytochrome-c), 3-(TGF-β1), 4-(Cox-2); by western blot; 5- T3-generating enzyme (Deiodinase I); RT-PCR; 6-cell migration, wound technique; 7-number of colonies. We evaluated the reversal effect of AT on the previously mentioned parameters. Results and Discussion: HCB increased cell proliferation and migration (PCNA levels 38%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
